Biohaven (NYSE:BHVN) Rating Increased to Sell at Wall Street Zen

Biohaven (NYSE:BHVN) was upgraded by analysts at Wall Street Zen from a “strong sell” rating to a “sell” rating in a research report issued on Saturday.

Several other brokerages also recently issued reports on BHVN. Leerink Partners restated an “outperform” rating and set a $15.00 price objective on shares of Biohaven in a research report on Tuesday, March 3rd. Deutsche Bank Aktiengesellschaft reiterated a “buy” rating on shares of Biohaven in a report on Friday. Weiss Ratings reissued a “sell (e+)” rating on shares of Biohaven in a research report on Tuesday, June 2nd. HC Wainwright reissued a “neutral” rating and issued a $10.00 price target on shares of Biohaven in a report on Tuesday, May 26th. Finally, Citigroup upped their price objective on Biohaven from $14.00 to $17.00 and gave the company a “buy” rating in a research report on Thursday, April 2nd. Two equities research analysts have rated the stock with a Strong Buy rating, ten have given a Buy rating, five have issued a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average price target of $22.27.

Biohaven Stock Performance

NYSE:BHVN opened at $15.79 on Friday. The company has a current ratio of 7.41, a quick ratio of 7.41 and a debt-to-equity ratio of 1.87. The company has a market capitalization of $2.38 billion, a P/E ratio of -2.79 and a beta of 1.35. The firm has a 50-day moving average price of $10.89 and a two-hundred day moving average price of $10.83. Biohaven has a twelve month low of $7.48 and a twelve month high of $18.57.

Biohaven (NYSE:BHVN) last announced its quarterly earnings results on Monday, May 4th. The company reported ($0.88) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.86) by ($0.02). As a group, research analysts expect that Biohaven will post -3.1 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Biohaven

Several institutional investors and hedge funds have recently modified their holdings of BHVN. AQR Capital Management LLC grew its stake in Biohaven by 49.4% in the 1st quarter. AQR Capital Management LLC now owns 114,849 shares of the company’s stock worth $2,761,000 after acquiring an additional 37,981 shares during the period. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. lifted its stake in shares of Biohaven by 32.4% during the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 71,833 shares of the company’s stock worth $1,747,000 after purchasing an additional 17,562 shares during the period. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC lifted its stake in shares of Biohaven by 7.5% during the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 589,615 shares of the company’s stock worth $14,174,000 after purchasing an additional 41,040 shares during the period. Intech Investment Management LLC boosted its holdings in shares of Biohaven by 80.3% during the first quarter. Intech Investment Management LLC now owns 61,598 shares of the company’s stock worth $1,481,000 after purchasing an additional 27,433 shares during the last quarter. Finally, Quantbot Technologies LP boosted its holdings in shares of Biohaven by 1,097.8% during the second quarter. Quantbot Technologies LP now owns 8,840 shares of the company’s stock worth $125,000 after purchasing an additional 8,102 shares during the last quarter. Hedge funds and other institutional investors own 88.78% of the company’s stock.

Biohaven Company Profile

Biohaven Ltd. (NYSE BHVN) is a clinical-stage biopharmaceutical company dedicated to developing and commercializing therapies for neurological and neurovascular diseases. Founded in 2013 as a spin-out from Yale University, Biohaven focuses on addressing high-unmet medical needs through innovative small-molecule and peptide-based platforms. The company is headquartered in New Haven, Connecticut, and maintains research activities across the United States, with collaborative ties in Europe and Asia via strategic partnerships.

The company’s most advanced program centers on calcitonin gene-related peptide (CGRP) receptor antagonists for the acute and preventive treatment of migraine.